| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 7, 2009
-- Fiscal third quarter revenue from continuing operations increased $25 million, or 5%, to $506 million as compared to $481 million this quarter a year ago -- Fiscal third quarter earnings from...
-
May 6, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on June 16, 2009 to shareholders of record on May...
-
Mar 24, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10%...
-
Mar 17, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Cobrek Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a...
-
Feb 20, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that has begun shipping over-the-counter (OTC) Ibuprofen and Diphenhydramine Citrate Tablets, 200/38 mg. The product will be marketed...
-
Feb 3, 2009- Fiscal second quarter revenue increased $126 million, or 29%, to $561 million as compared to $435 million this quarter a year ago
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2009 second quarter and six months that ended December 27, 2008. Perrigo Company (in thousands, except per...
-
Jan 28, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on March 17, 2009 to shareholders of record on...
-
Jan 21, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal year 2009 on Tuesday, February 3, 2009 at approximately 8:00 a.m....
-
Jan 7, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12, at...
-
Dec 29, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...